For your adult patients with relapsed or
refractory multiple myeloma in combination
with
carfilzomib and dexamethasone (Kd) or pomalidomide and dexamethasone (Pd)

THIS IS WHAT EFFICACY
LOOKS LIKE WITH sarclisa

Choose sarclisa + Kd or Pd as early as first relapse
for improved PFS vs Kd or Pd alone1

Consider sarclisa + Kd
at first relapse1

Explore Patient Types

See the phase 3 ikema trial

Explore sarclisa + Kd

See the phase 3
icaria-MM trial

Explore sarclisa + Pd

ikema mPFS: Not yet reached (NR) with sarclisa + Kd (n=179) vs 20.27 months with Kd alone (n=123), HR=0.548 (95% CI: 0.37, 0.82; P=0.0032).1

icaria-MM mPFS: 11.53 months with sarclisa + Pd (n=154) vs 6.47 months with Pd alone (n=153), HR=0.596 (95% CI: 0.44, 0.81; P=0.0010).1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
for Multiple Myeloma recommend isatuximab-irfc (sarclisa) as a Category 1 Preferred option for early relapses2*

  • In combination with pomalidomide and dexamethasone
  • In combination with carfilzomib and dexamethasone

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

*1-3 prior therapies.2
mPFS=median progression-free survival; NCCN=National Comprehensive Cancer Network; PFS=progression-free survival.

References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2022. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed August 20, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.
Back to topTop